HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 998-1004

  Osibogun, O ^a   Ogunmoroti, O ^a,b   Michos, E D ^c   Spatz, E S ^d,e   Olubajo, B ^f   Nasir, K ^a,b   Madhivanan, P ^a   Maziak, W ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b MIAMI CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d YALE NEW HAVEN HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SciMetrika   (United States)

Author keywords

cardiovascular disease; HIV HCV coinfection; metaanalysis

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX; SMOKING; SYSTEMATIC REVIEW; COMPLICATION; FEMALE; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; META ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK; SOCIOECONOMICS; VIROLOGY;

CARDIOVASCULAR DISEASES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RISK; SOCIOECONOMIC FACTORS;

EID: 85021256481     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12725     Document Type: Review

References (46)

1. WHO. HIV/AIDS. 2016. http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed October 2016.
2. WHO. Hepatitis C. 2016. http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed October 2016.
3. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342.
4. UNAIDS. FACT SHEET 2016. 2016. http://www.unaids.org/en/resources/fact-sheet. Accessed October 2016.
5. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48:353-367.
6. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
8. Chew KW, Hua L, Bhattacharya D, et al. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2014;1:ofu104.
9. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
10. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225-232.
11. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study PLoS One. 2012;7:e31527.
12. de Larranaga GF, Peres Wingeyer SDA, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis. 2006;25:98-103.
13. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468.
14. Wheeler AL, Scherzer R, Lee D, et al. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection. AIDS. 2014;28:49-58.
15. Bedimo R, Ghurani R, Nsuami M, et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med. 2006;7:530-536.
16. Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS. 2007;21:479-491.
17. Osibogun O. HIV/HCV coinfection and the risk of cardiovascular disease: a systematic review and meta-analysis. PROSPERO 2016:CRD42016037474. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037474. Accessed October 2016.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint–preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89:873-880.
19. Newcastle-Ottawa quality assessment scale cohort studies. http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf. Accessed June 2016.
20. Freiberg MS, Chang CC, Skanderson M, et al. Veterans Aging Cohort Study. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4:425-432.
21. Fernandez-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47-52.
22. Gillis J, Smieja M, Cescon A, et al. Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther. 2014;19:309-317.
23. Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, Samet JH. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS. 2007;21:193-197.
24. Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract. 2013;67:6-13.
25. Weber R, Sabin C, Reiss P, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A: D Cohort Study. Antivir Ther. 2010;15:1077-1086.
26. Tien PC, Schneider MF, Cole SR, et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS. 2009;23:1781-1784.
27. Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis. 2012;222:274-277.
28. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351-358.
29. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737-743.
30. Ye Y, Zeng Y, Li X, et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr. 2010;53:276-278.
31. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205(Suppl 3):S355-S361.
32. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-1631.
33. Oliveira CP, Kappel CR, Siqueira ER, et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2013;164:221-226.
34. Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail. 2009;15:451-456.
35. McKibben RA, Haberlen SA, Post WS, et al. A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study. J Infect Dis. 2016;213:257-265.
36. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010;8:1002-1012.
37. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(Suppl 1):S10-S15.
38. van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25:1083-1091.
39. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men–New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60:945-950.
40. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230-238.
41. Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ. Naggie S. Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS. 2012;26:541-545.
42. Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339.
43. Pascual-Pareja JF, Caminoa A, Larrauri C, et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS. 2009;23:971-975.
44. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. November 2016. http://www.hcvguidelines.org. Accessed November 2016.
45. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345:351-358.
46. Lucas GM, Atta MG, Fine DM, et al. HIV, Cocaine Use, and Hepatitis C Virus: a Triad of Nontraditional Risk Factors for Subclinical Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2016;36:2100-2107.